Michael Skynner
Chief Tech/Sci/R&D Officer presso BICYCLE THERAPEUTICS PLC
Patrimonio netto: 2 M $ in data 31/03/2024
Profilo
Michael Skynner is the founder of Cambridge Biotechnology Ltd.
(founded in 2001).
He is currently the Chief Technology Officer at Bicycle Therapeutics Plc (since 2016) and the Chief Operating Officer at Bicycle Therapeutics, Inc. (since 2018).
Previously, he worked at Pfizer Inc. as the Head-Rare Disease Alliances (2013-2016).
He holds a doctorate degree from Imperial College London.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 03/04/2024 | 94 884 ( 0.32% ) | 2 M $ | 31/03/2024 |
Posizioni attive di Michael Skynner
| Società | Posizione | Inizio |
|---|---|---|
| BICYCLE THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 03/01/2022 |
Bicycle Therapeutics, Inc.
 Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The private company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | Chief Operating Officer | 01/01/2018 |
Precedenti posizioni note di Michael Skynner
| Società | Posizione | Fine |
|---|---|---|
| PFIZER, INC. | Corporate Officer/Principal | 01/01/2016 |
Cambridge Biotechnology Ltd.
 Cambridge Biotechnology Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Biotechnology Ltd. is a wholly owned subsidiary of Biovitrum AB. The company's founders originate from a Pfizer Global Research & Development drug discovery team in what had previously been the Parke-Davis Neuroscience Research Centre. The founders, together with some key academic collaborators, created the company to exploit several opportunities in drug discovery as well as their world class 'gene to lead' drug discovery capability. The company has well equipped modern laboratory and office facilities situated on the Babraham Research Campus. This location allows the company to forge links with a host of world class research groups based in the Cambridge area. CBT is always looking to identify potential partner companies for both in-licensing and risk-sharing drug discovery ventures. | Founder | 01/05/2005 |
Formazione di Michael Skynner
| Imperial College London | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PFIZER, INC. | Health Technology |
| BICYCLE THERAPEUTICS PLC | Health Technology |
| Aziende private | 2 |
|---|---|
Cambridge Biotechnology Ltd.
Cambridge Biotechnology Ltd. Miscellaneous Commercial ServicesCommercial Services Cambridge Biotechnology Ltd. is a wholly owned subsidiary of Biovitrum AB. The company's founders originate from a Pfizer Global Research & Development drug discovery team in what had previously been the Parke-Davis Neuroscience Research Centre. The founders, together with some key academic collaborators, created the company to exploit several opportunities in drug discovery as well as their world class 'gene to lead' drug discovery capability. The company has well equipped modern laboratory and office facilities situated on the Babraham Research Campus. This location allows the company to forge links with a host of world class research groups based in the Cambridge area. CBT is always looking to identify potential partner companies for both in-licensing and risk-sharing drug discovery ventures. | Commercial Services |
Bicycle Therapeutics, Inc.
Bicycle Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Bicycle Therapeutics Plc, Bicycle Therapeutics, Inc. develops medicines and therapeutics for cancer treatment. The private company is based in Lexington, MA. The company was founded in 2009 by Kevin Lee. Kevin Lee has been the CEO since 2009. | Health Technology |
- Borsa valori
- Insiders
- Michael Skynner
